Literature DB >> 25373854

Timing and characteristics of radiation pneumonitis after stereotactic body radiotherapy for peripherally located stage I lung cancer.

Ayae Kanemoto1, Yasuo Matsumoto, Tadashi Sugita.   

Abstract

BACKGROUND: This study was conducted to determine the timing and characteristics of radiation pneumonitis (RP) associated with stereotactic body radiotherapy (SBRT) for stage I lung cancer.
METHODS: Two hundred thirty-one patients treated with SBRT using 52 Gy in 4 fractions were identified. Control rate, RP incidence rate, and predictive factors and timing of RP were evaluated retrospectively.
RESULTS: The 3-year overall survival and local control rates were 80.7 and 92.0 %, respectively. The grade ≥2 RP rate was 13.0 %; no grade 4-5 RP occurred. The most statistically significant predictive factor of grade ≥2 RP was V10. The median intervals to first graphical appearance were 4.2 and 2.5 months for grade 1 and grade 2-3 RP, respectively. Median intervals to maximum radiological density change were 6.0 and 4.6 months for grade 1 and grade 2-3 RP, respectively. A significantly different interval to first graphical appearance between grade 1 and grade 2-3 RP was observed; no significantly different interval to maximum radiological density change was noted.
CONCLUSIONS: The first graphical appearance of grade ≥2 RP was earlier than that of grade 1 RP, although the timing of maximum radiological density change was not significantly different.

Entities:  

Mesh:

Year:  2014        PMID: 25373854     DOI: 10.1007/s10147-014-0766-3

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  14 in total

1.  A dose-volume analysis of radiation pneumonitis in non-small cell lung cancer patients treated with stereotactic body radiation therapy.

Authors:  R Bryan Barriger; Jeffrey A Forquer; Jeffrey G Brabham; David L Andolino; Ronald H Shapiro; Mark A Henderson; Peter A S Johnstone; Achilles J Fakiris
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-10-29       Impact factor: 7.038

2.  Clinical and dosimetric predictors of radiation pneumonitis in a large series of patients treated with stereotactic body radiation therapy to the lung.

Authors:  Ryan Baker; Gang Han; Siriporn Sarangkasiri; MaryLou DeMarco; Carolyn Turke; Craig W Stevens; Thomas J Dilling
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-08-25       Impact factor: 7.038

Review 3.  Stereotactic body radiation therapy for stage I non-small-cell lung cancer: a historical overview of clinical studies.

Authors:  Hiroshi Onishi; Tsutomu Araki
Journal:  Jpn J Clin Oncol       Date:  2013-02-21       Impact factor: 3.019

4.  Dose--volume metrics associated with radiation pneumonitis after stereotactic body radiation therapy for lung cancer.

Authors:  Yukinori Matsuo; Keiko Shibuya; Mitsuhiro Nakamura; Masaru Narabayashi; Katsuyuki Sakanaka; Nami Ueki; Ken Miyagi; Yoshiki Norihisa; Takashi Mizowaki; Yasushi Nagata; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-03-19       Impact factor: 7.038

5.  Predicting radiation pneumonitis after stereotactic ablative radiation therapy in patients previously treated with conventional thoracic radiation therapy.

Authors:  Hui Liu; Xu Zhang; Yevgeniy Y Vinogradskiy; Stephen G Swisher; Ritsuko Komaki; Joe Y Chang
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

6.  Early graphical appearance of radiation pneumonitis correlates with the severity of radiation pneumonitis after stereotactic body radiotherapy (SBRT) in patients with lung tumors.

Authors:  Atsuya Takeda; Toshio Ohashi; Etsuo Kunieda; Tatsuji Enomoto; Naoko Sanuki; Toshiaki Takeda; Naoyuki Shigematsu
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-07-01       Impact factor: 7.038

Review 7.  Radiation injury of the lung after stereotactic body radiation therapy (SBRT) for lung cancer: a timeline and pattern of CT changes.

Authors:  Anna Linda; Marco Trovo; Jeffrey D Bradley
Journal:  Eur J Radiol       Date:  2009-12-01       Impact factor: 3.528

Review 8.  Systemic review of the patterns of failure following stereotactic body radiation therapy in early-stage non-small-cell lung cancer: clinical implications.

Authors:  Alexander Chi; Zhongxing Liao; Nam P Nguyen; Jiahong Xu; Baldassarre Stea; Ritsuko Komaki
Journal:  Radiother Oncol       Date:  2010-01-13       Impact factor: 6.280

Review 9.  Stereotactic body radiation therapy for lung cancer.

Authors:  Charles B Simone; Brian Wildt; Andrew R Haas; Greg Pope; Ramesh Rengan; Stephen M Hahn
Journal:  Chest       Date:  2013-06       Impact factor: 9.410

10.  Early and late lung radiographic injury following stereotactic body radiation therapy (SBRT).

Authors:  Marco Trovo; Anna Linda; Issam El Naqa; Cylen Javidan-Nejad; Jeffrey Bradley
Journal:  Lung Cancer       Date:  2009-11-11       Impact factor: 5.705

View more
  12 in total

1.  Predicting risk factors for radiation pneumonitis after stereotactic body radiation therapy for primary or metastatic lung tumours.

Authors:  Mitsuru Okubo; Tomohiro Itonaga; Tatsuhiko Saito; Sachika Shiraishi; Ryuji Mikami; Hidetugu Nakayama; Akira Sakurada; Shinji Sugahara; Kiyoshi Koizumi; Koichi Tokuuye
Journal:  Br J Radiol       Date:  2017-04-06       Impact factor: 3.039

Review 2.  Simple Factors Associated With Radiation-Induced Lung Toxicity After Stereotactic Body Radiation Therapy of the Thorax: A Pooled Analysis of 88 Studies.

Authors:  Jing Zhao; Ellen D Yorke; Ling Li; Brian D Kavanagh; X Allen Li; Shiva Das; Moyed Miften; Andreas Rimner; Jeffrey Campbell; Jinyu Xue; Andrew Jackson; Jimm Grimm; Michael T Milano; Feng-Ming Spring Kong
Journal:  Int J Radiat Oncol Biol Phys       Date:  2016-03-25       Impact factor: 7.038

3.  Optimizing the flattening filter free beam selection in RapidArc®-based stereotactic body radiotherapy for Stage I lung cancer.

Authors:  J-Y Lu; Z Lin; P-X Lin; B-T Huang
Journal:  Br J Radiol       Date:  2015-07-02       Impact factor: 3.039

4.  Radiobiological modeling analysis of the optimal fraction scheme in patients with peripheral non-small cell lung cancer undergoing stereotactic body radiotherapy.

Authors:  Bao-Tian Huang; Jia-Yang Lu; Pei-Xian Lin; Jian-Zhou Chen; De-Rui Li; Chuang-Zhen Chen
Journal:  Sci Rep       Date:  2015-12-11       Impact factor: 4.379

5.  Pretreatment Factors Influencing Radiation Pneumonitis after Stereotactic Body Radiation Therapy in the Treatment of Lung Cancer.

Authors:  Alexander A Harris; Kyle Stang; Christina Small; Ryan Hutten; Fiori Alite; Bahman Emami; Matthew Harkenrider
Journal:  Cureus       Date:  2020-03-29

6.  Rapid Development of Clinically Symptomatic Radiation Recall Pneumonitis Immediately Following COVID-19 Vaccination.

Authors:  Cole R Steber; Janardhana Ponnatapura; Ryan T Hughes; Michael K Farris
Journal:  Cureus       Date:  2021-04-05

7.  Lung Function After Stereotactic Body Radiation Therapy for Early-Stage Non-Small Cell Lung Cancer, Changes and Predictive Markers.

Authors:  Janna Berg; Christina Ramberg; Jon Olav Sulheim Haugstvedt; May-Bente Bengtson; Anne-Marie Gabrielsen; Odd Terje Brustugun; Ann Rita Halvorsen; Åslaug Helland
Journal:  Front Oncol       Date:  2021-05-24       Impact factor: 6.244

8.  Radiobiological modeling of two stereotactic body radiotherapy schedules in patients with stage I peripheral non-small cell lung cancer.

Authors:  Bao-Tian Huang; Zhu Lin; Pei-Xian Lin; Jia-Yang Lu; Chuang-Zhen Chen
Journal:  Oncotarget       Date:  2016-06-28

9.  Radiotherapy increases plasma levels of tumoral cell-free DNA in non-small cell lung cancer patients.

Authors:  Shun-Ichiro Kageyama; Keiji Nihei; Katsuyuki Karasawa; Takeshi Sawada; Fumiaki Koizumi; Shigeo Yamaguchi; Shunsuke Kato; Hidehiro Hojo; Atsuhi Motegi; Katsuya Tsuchihara; Tetsuo Akimoto
Journal:  Oncotarget       Date:  2018-04-10

10.  Interobserver reliability in describing radiographic lung changes after stereotactic body radiation therapy.

Authors:  Noah S Kalman; Geoffrey D Hugo; Jenna M Kahn; Sherry S Zhao; Nuzhat Jan; Rebecca N Mahon; Elisabeth Weiss
Journal:  Adv Radiat Oncol       Date:  2018-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.